Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The whitehall II study

Christian Herder, Eric J. Brunner, Wolfgang Rathmann, Klaus Strassburger, A. Tabák, Nanette C. Schloot, Daniel R. Witte

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95% CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.

Original languageEnglish
Pages (from-to)421-423
Number of pages3
JournalDiabetes Care
Volume32
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Interleukin-1 Receptors
Type 2 Diabetes Mellitus
Anti-Inflammatory Agents
Interleukins
Antigen-Antibody Complex
Case-Control Studies
Research Design
Up-Regulation
Odds Ratio
Cytokines
Glucose
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes : The whitehall II study. / Herder, Christian; Brunner, Eric J.; Rathmann, Wolfgang; Strassburger, Klaus; Tabák, A.; Schloot, Nanette C.; Witte, Daniel R.

In: Diabetes Care, Vol. 32, No. 3, 03.2009, p. 421-423.

Research output: Contribution to journalArticle

Herder, Christian ; Brunner, Eric J. ; Rathmann, Wolfgang ; Strassburger, Klaus ; Tabák, A. ; Schloot, Nanette C. ; Witte, Daniel R. / Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes : The whitehall II study. In: Diabetes Care. 2009 ; Vol. 32, No. 3. pp. 421-423.
@article{d4f069deb95b481eb374f7cc5cfafdca,
title = "Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The whitehall II study",
abstract = "OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95{\%} CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.",
author = "Christian Herder and Brunner, {Eric J.} and Wolfgang Rathmann and Klaus Strassburger and A. Tab{\'a}k and Schloot, {Nanette C.} and Witte, {Daniel R.}",
year = "2009",
month = "3",
doi = "10.2337/dc08-1161",
language = "English",
volume = "32",
pages = "421--423",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes

T2 - The whitehall II study

AU - Herder, Christian

AU - Brunner, Eric J.

AU - Rathmann, Wolfgang

AU - Strassburger, Klaus

AU - Tabák, A.

AU - Schloot, Nanette C.

AU - Witte, Daniel R.

PY - 2009/3

Y1 - 2009/3

N2 - OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95% CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.

AB - OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95% CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.

UR - http://www.scopus.com/inward/record.url?scp=64749095071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749095071&partnerID=8YFLogxK

U2 - 10.2337/dc08-1161

DO - 10.2337/dc08-1161

M3 - Article

C2 - 19073760

AN - SCOPUS:64749095071

VL - 32

SP - 421

EP - 423

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -